EGFR and neoplasm: This regulatory network has actionable interfaces with key therapies; preclinical evidence links the miR-200c/LIN28B axis to acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) [4], while the circuit’s control over PD-L1 expression modulates the tumor immune microenvironment [5].